Page 269 - 82_ex2

U. Etxeberria, Fermín I. Milagro, Carlos J. González-Navarro, J. Alfredo Martínez
American College of Cardiology/American Heart
Association Task Force on Practice Guidelines and
The Obesity Society. J Am Coll Cardiol 2014; 63:
2985-3023.
218.Fitch A, Everling L, Fox C, Goldberg J. et al.
Prevention and management of obesity for adults.
2013. Disponible en:
(https://wwwicsiorg/guidelines__more/catalog_guideli
nes_and_more/catalog_guidelines/catalog_endocrine_
guidelines/obesity__adults/)
219.Kushner RF. Weight loss strategies for treatment of
obesity. Prog Cardiovasc Dis 2014; 56: 465-72.
220.Solas M, Milagro FI, Martínez-Urbistondo D,
Ramirez MJ, Martínez JA. Precision Obesity
Treatments Including Pharmacogenetic and
Nutrigenetic Approaches. Trends Pharmacol Sci.
2016; [Epub ahead of print].
221.Di Dalmazi G, Vicennati V, Pasquali R, Pagotto U.
The unrelenting fall of the pharmacological treatment
of obesity. Endocrine 2013; 44: 598-609.
222.Vasudeva N, Yadav N, Sharma SK. Natural products:
a safest approach for obesity. Chin J Integr Med 2012;
18: 473-80.
223.Mohamed GA, Ibrahim SRM, Elkhayat ES, El Dine
RS. Natural anti-obesity agents. B-FOPCU, 2014; 52:
269-84.
224.Pan MH, Lai CS, Ho CT. Anti-inflammatory activity
of natural dietary flavonoids. Food Funct 2010; 1: 15-
31.
225.Andrés-Lacueva C., Medina-Remon A., Llorach R.,
Urpi-Sarda M. et al. Phenolic Compounds: Chemistry
and Occurrence in Fruits and Vegetables. En: Fruit
and Vegetable Phytochemicals. Wiley-Blackwell
2009: pp. 53-88.
226.Nabavi SF, Russo GL, Daglia M, Nabavi SM. Role of
quercetin as an alternative for obesity treatment: you
are what you eat!. Food Chem 2015; 179: 305-310.
227.Gambini J., Ingles M., Olaso G., Lopez-Grueso R. et
al.. Properties of Resveratrol: In Vitro and In Vivo
Studies about Metabolism, Bioavailability, and
Biological Effects in Animal Models and Humans.
Oxid Med Cell Longev 2015; 2015: 837042.
228.Verbeke KA, Boobis AR, Chiodini A, Edwards CA. et
al. Towards microbial fermentation metabolites as
markers for health benefits of prebiotics. Nutr Res
Rev 2015; 28: 42-66.
229.Van den Abbeele P, Verstraete W, El Aidy S,
Geirnaert A, Van de Wiele T. Prebiotics, faecal
transplants and microbial network units to stimulate
biodiversity of the human gut microbiome. Microb
Biotechnol 2013; 6: 335-40.
230.Borgia G, Maraolo AE, Foggia M, Buonomo AR,
Gentile I. Fecal microbiota transplantation for
Clostridium difficile infection: back to the future.
Expert Opin Biol Ther 2015; 15: 1001-14.
231.Borody TJ, Khoruts A. Fecal microbiota
transplantation and emerging applications. Nat Rev
Gastroenterol Hepatol 2012; 9: 88-96.
258 @Real Academia Nacional de Farmacia. Spain
232.Xu MQ, Cao HL, Wang WQ, Wang S. et al. Fecal
microbiota transplantation broadening its application
beyond intestinal disorders. World J Gastroenterol
2015; 21: 102-11.
233.Singh R, Nieuwdorp M, ten Berge IJ, Bemelman FJ,
Geerlings SE. The potential beneficial role of faecal
microbiota transplantation in diseases other than
Clostridium difficile infection. Clin Microbiol Infect
2014; 20: 1119-1125.
234.Thomas T, Gilbert J, Meyer F. Metagenomics - a
guide from sampling to data analysis. Microb Inform
Exp 2012; 2: 3.
235.Hamady M, Knight R. Microbial community profiling
for human microbiome projects: Tools, techniques,
and challenges. Genome Res 2009; 19: 1141-52.
236.Rondon MR, August PR, Bettermann AD, Brady SF.
et al. Cloning the soil metagenome: a strategy for
accessing the genetic and functional diversity of
uncultured microorganisms. Appl Environ Microbiol
2000; 66: 2541-7.
237.Preidis GA, Hotez PJ. The newest "omics"-
metagenomics and metabolomics-enter the battle
against the neglected tropical diseases. PLoS Negl
Trop Dis 2015; 9: e0003382.
238.Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V. et
al. An obesity-associated gut microbiome with
increased capacity for energy harvest. Nature 2006;
444: 1027-31.
239.Rabot S, Membrez M, Bruneau A, Gerard P. et al.
Germ-free C57BL/6J mice are resistant to high-fat-
diet-induced insulin resistance and have altered
cholesterol metabolism. FASEB J 2010; 24: 4948-
4959.
240.Ridaura VK, Faith JJ, Rey FE, Cheng J. et al. Gut
microbiota from twins discordant for obesity modulate
metabolism in mice. Science 2013; 341: 1241214.
241.Duca FA, Sakar Y, Lepage P, Devime F. et al.
Replication of obesity and associated signaling
pathways through transfer of microbiota from obese-
prone rats. Diabetes 2014; 63: 1624-36.
Lista de abreviaturas
AGCC, Ácidos grasos de cadena corta; AMPK, Proteín
quinasa activada por AMP; ANGPTL-4, Proteína similar a
angiopoyetina 4; BDNF, Factor neurotrófico derivado del
cerebro; BMI, Índice de masa corporal; ChREBP, Proteína
de unión al elemento de respuesta a hidratos de carbono;
COX2, Ciclooxigenasa-2; DM2, Diabetes Mellitus tipo 2;
ECV, Enfermedad/es cardiovascular/es; EPS,
Exopolisacáridos; FFR, Receptor de ácido graso libre;
FIAF, Factor adiposo inducido por el ayuno; FMT,
Trasplante fecal de microbiota; GF, Germ-free; GI,
Gastrointestinal; GLP-1, Péptido similar al glucagón tipo
1; HAT, Acetiltransferasa de histonas; HDAC,
Desacetilasa de histonas; HMP, Human Microbiome
Project; IBD, Enfermedad inflamatoria intestinal; IBS,
Síndrome de colon irritable; IL, Interleucina; IMOS,
Isomalto-oligosacáridos; iNOS, Óxido nítrico sintasa